ELEVATE-RR summary: CALQUENCE▼ (acalabrutinib) vs ibrutinib
A summary of the ELEVATE-R/R trial: Calquence vs. ibrutinib in previously treated CLL.
Found this useful? You might also be interested in:
Adverse events should be reported
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.
September 2025 I GB-69434